Related Experiment Video

Updated: Jun 23, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

[Sorafenib reverses multidrug resistance of hepatoma cells in vitro]

Li Wei1, Na Huang, Lin Yang

  • 1Center of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. bensonlily@163.com

Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University
|May 23, 2009
PubMed
Abstract

Insights

Sorafenib effectively reverses multidrug resistance (MDR) in hepatoma cells by down-regulating mdr1 gene expression. This action increases chemotherapeutic agent accumulation, offering a potential strategy to overcome drug resistance in liver cancer treatment.

Area of Science:

  • Hepatocellular Carcinoma Research
  • Cancer Pharmacology
  • Molecular Oncology

Background:

  • Hepatocellular carcinoma (HCC) often develops multidrug resistance (MDR), limiting treatment efficacy.
  • MDR in hepatoma cells is frequently associated with the overexpression of efflux pumps like P-glycoprotein (P-gp).
  • Identifying agents that can overcome MDR is crucial for improving HCC patient outcomes.

Purpose of the Study:

  • To investigate the potential of sorafenib in reversing MDR in BEL-7402/FU hepatoma cells.
  • To elucidate the underlying mechanisms by which sorafenib might overcome drug resistance.

Main Methods:

  • Dose-response curves were established using MTT assays.
  • Flow cytometry assessed intracellular Rho123 concentration and P-glycoprotein (P-gp) expression.
  • RT-PCR was utilized to quantify mdr1 gene expression.

Main Results:

  • Sorafenib at 4 micromol/L reversed MDR in BEL-7402/FU cells against ADM, 5-FU, GEM, and DDP.
  • This concentration of sorafenib partially down-regulated P-gp expression.
  • A 27.3% reduction in mdr1 gene expression was observed with sorafenib treatment.

Conclusions:

  • Sorafenib demonstrates efficacy in reversing MDR in human hepatoma cells.
  • The mechanism involves the down-regulation of mdr1 gene expression.
  • This leads to increased intracellular accumulation of chemotherapeutic agents, potentially enhancing treatment effectiveness.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...